To provide state-of-the-art comprehensive, multidisciplinary care to patients, families, and caregivers in a personalized setting.
The FDA has approved OCREVUS (ocrelizumab) for primary progressive and relapsing forms of MS! Our team at The Elliot Lewis Center participated in the pivotal clinical trials for ocrelizumab and is thrilled about this long awaited approval! This is a historic moment, as OCREVUS is the first and only approved disease modifying therapy for patients with PPMS. Additional details about OCREVUS...